AlphaCentric Advisors’s 2seventy bio TSVT Stock Holding History

AlphaCentric Advisors’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-657,500	Closed	-$2.58M	–	281
2023 Q3	$2.58M	Buy	657,500 +477,500	+265%	+$3.13M	1.46%	18
2023 Q2	$1.82M	Sell	180,000 -122,500	-40%	-$1.3M	1.01%	33
2023 Q1	$3.09M	Buy	302,500 +122,500	+68%	+$1.4M	2.13%	6
2022 Q4	$1.69M	Buy	180,000 +113,000	+169%	+$1.59M	1.67%	9
2022 Q3	$975K	Buy	+67,000	New	+$994K	1%	25
2021 Q4	$256K	Buy	+10,000	New	+$312K	0.07%	89

Other funds holding TSVT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

AlphaCentric Advisors's TSVT Position: Q4 2023 in Review

AlphaCentric Advisors sold out of 2seventy bio (TSVT) in Q4 2023, closing a stake of 657,500 shares — an estimated $2.58M sold.

AlphaCentric Advisors first reported a position in TSVT in Q4 2021 and held it in 6 quarters. The position peaked at $3.09M in Q1 2023. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2023.

AlphaCentric Advisors reported no remaining 2seventy bio position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 657,500 2seventy bio shares in Q4 2023, an estimated $2.58M.
AlphaCentric Advisors first reported a position in 2seventy bio in Q4 2021 and held it in 6 quarters.
AlphaCentric Advisors's 2seventy bio position peaked at $3.09M in Q1 2023.
116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.